PepGen Inc.

PepGen Inc.

PEPG·NASDAQ

$1.46

+3.0%
HealthcareBiotechnology

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

At a Glance

Live Snapshot
Market Cap$101.28M
EPS-2.1200
P/E Ratio-0.69
Earnings Date08/06/2026

pepg

Other Current Liabilities

Last Annual Value

8.64M

3-Year CAGR

52%

5-Year CAGR

215%

10-Year CAGR

%

PepGen Inc.

PepGen Inc. Competitors Analysis of Other Current Liabilities

PEPG · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
PEPG logo
PepGen Inc.
NASDAQ:PEPG
8.64M
53.9%48.3%N/A 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
51.71M
-1.9%34.7%N/A
NKTX logo
Nkarta, Inc.
NASDAQ:NKTX
13.29M
25.5%168.1%N/A
6.92M
-50.2%N/AN/A
4.18M
147.0%N/AN/A
8.86M
N/A49.5%N/A
13.31M
12.4%19.4%N/A
7.02M
22.7%118.2%N/A
3.69M
44.8%-23.0%N/A
43.83M
134.0%133.5%109.4%
16.84M
655.9%163.1%35.8%
PepGen Inc.

PepGen Inc. Fair Value Envelope

PEPG · NASDAQ

Our analysis suggests that PEPG has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.4642, this represents a potential HIDDEN relative to our calculated worth for PepGen Inc..

Intrinsic Value
Current Price: $1.4642